MWNA
NGNE icon

Marshall Wace North America’s Neurogene NGNE Stock Holding History

Marshall Wace North America’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,862
Closed -$806K – 1584
2018
Q1 		$806K Buy
+2,862
New +$790K ﹤0.01% 1050

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UONDDL
University of Notre Dame du Lac South Bend, Indiana $66.8M AUM 43.52% 1-Year Est. Return

Marshall Wace North America's NGNE Position: Q2 2018 in Review

Marshall Wace North America sold out of Neurogene (NGNE) in Q2 2018, closing a stake of 2,862 shares — an estimated $806K sold.

Marshall Wace North America first reported a position in NGNE in Q1 2018 and held it in 1 quarter. The position peaked at $806K in Q1 2018. 44 funds tracked by Wall St. Rank hold NGNE as of Q2 2018.

  • Marshall Wace North America reported no remaining Neurogene position as of Q2 2018 after selling out during the quarter.
  • Marshall Wace North America sold 2,862 Neurogene shares in Q2 2018, an estimated $806K.
  • Marshall Wace North America first reported a position in Neurogene in Q1 2018 and held it in 1 quarter.
  • Marshall Wace North America's Neurogene position peaked at $806K in Q1 2018.
  • 44 funds tracked by Wall St. Rank held Neurogene as of Q2 2018.

Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.